Frank\u00adfurt, London and Munich \u2014 KKR Health Care Growth Fund II has made an invest\u00adment in German biophar\u00admaceu\u00adti\u00adcal rese\u00adarch and deve\u00adlo\u00adp\u00adment company Corio\u00adlis Pharma. As part of the tran\u00adsac\u00adtion, Corio\u00adlis Pharma will enter into a stra\u00adte\u00adgic growth part\u00adner\u00adship with Fron\u00adtier Bioso\u00adlu\u00adti\u00adons, a global phar\u00admaceu\u00adti\u00adcal services plat\u00adform newly formed by KKR and Flerie Invest AB.<\/p>\n
KKR\u2019s invest\u00adment will enable Corio\u00adlis to embark on the next phase of growth in its core busi\u00adness, expand its port\u00adfo\u00adlio of services along the value chain, streng\u00adthen its global presence and conti\u00adnue to inte\u00adgrate AI-based technologies.<\/p>\n
Corio\u00adlis is expec\u00adted to gain access to KKR\u2019s global health\u00adcare network and Fron\u00adtier<\/span> Bioso\u00adlu\u00adti\u00adons to expand Corio\u00adlis\u2019 global opera\u00adti\u00adons and growth plans in inno\u00adva\u00adtive, high-value formu\u00adla\u00adtion rese\u00adarch and deve\u00adlo\u00adp\u00adment services.<\/p>\n \u201cSince Corio\u00adlis was foun\u00added 15 years ago, our vision has been to revo\u00adlu\u00adtio\u00adnize the biophar\u00admaceu\u00adti\u00adcal drug deve\u00adlo\u00adp\u00adment process by inte\u00adgra\u00adting inno\u00adva\u00adtive digi\u00adtal formu\u00adla\u00adtion approa\u00adches from deve\u00adlo\u00adp\u00adment through commer\u00adcial products,\u201d said Corio\u00adlis co-foun\u00adders and board members Michael and Thomas Wiggen\u00adhorn<\/strong>. The coope\u00adra\u00adtion with KKR should enable major steps forward in this regard and further expand the company\u2019s scien\u00adti\u00adfic leader\u00adship posi\u00adtion, he said.<\/p>\n The Gibson Dunn team, led by London part\u00adner and co-head of the private equity prac\u00adtice in Europe Wim De Vlie\u00adger and Frank\u00adfurt part\u00adners Dr. Wilhelm Rein\u00adhardt and Dr. Jan Schu\u00adbert, included London coun\u00adsel Dr. Jakob Egle and asso\u00adcia\u00adtes Sonja Rutt\u00admann, Dr. Dennis Seif\u00adarth (both Munich), Lisa Holl\u00adfel\u00adder (Frank\u00adfurt) and Gisele Zouein (London). Brussels anti\u00adtrust and compe\u00adti\u00adtion law part\u00adner Attila Borsos and London asso\u00adcia\u00adtes Ben Nunez and Robert Albert\u00adson Kill as well as corpo\u00adrate coun\u00adsel Dr. Birgit Friedl and asso\u00adciate Dr. Marcus Geiss (both Munich) supported the team. In Munich, part\u00adner Kai Gesing and asso\u00adcia\u00adtes Chris\u00adtoph Jacob and Yannick Ober\u00adacker advi\u00adsed on IP issues, while Frank\u00adfurt finance coun\u00adsel Alex\u00adan\u00adder Klein and asso\u00adciate Bastiaan Wolters advi\u00adsed on finan\u00adcing issues.<\/p>\n About Gibson Dunn<\/strong><\/p>\n Gibson, Dunn & Crut\u00adcher LLP is one of the leading inter\u00adna\u00adtio\u00adnal law firms and is ranked among the top law firms world\u00adwide in indus\u00adtry surveys and by autho\u00adri\u00adta\u00adtive publi\u00adca\u00adti\u00adons. With more than 1,800 lawy\u00aders in 20 offices, the firm has a global presence in all major econo\u00admic regi\u00adons. Gibson Dunn offices are loca\u00adted in Abu Dhabi, Brussels, Century City, Dallas, Denver, Dubai, Frank\u00adfurt, Hong Kong, Hous\u00adton, London, Los Ange\u00adles, Munich, New York, Orange County, Palo Alto, Paris, Beijing, San Fran\u00adcisco, Singa\u00adpore and Washing\u00adton, D.C. For more infor\u00adma\u00adtion, visit www.gibsondunn.com.<\/p>\n","protected":false},"excerpt":{"rendered":" Frank\u00adfurt, London and Munich \u2014 KKR Health Care Growth Fund II has made an invest\u00adment in German biophar\u00admaceu\u00adti\u00adcal rese\u00adarch and deve\u00adlo\u00adp\u00adment company Corio\u00adlis Pharma. As part of the tran\u00adsac\u00adtion, Corio\u00adlis Pharma will enter into a stra\u00adte\u00adgic growth part\u00adner\u00adship with Fron\u00adtier Bioso\u00adlu\u00adti\u00adons, a global phar\u00admaceu\u00adti\u00adcal services plat\u00adform newly formed by KKR and Flerie Invest AB. KKR\u2019s [\u2026]<\/p>\n","protected":false},"author":2,"featured_media":49581,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[886,1364,1365,1366,1367,1368,1369],"tags":[],"class_list":["post-49583","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general-en","category-featured-en","category-private-equity-en","category-news-en","category-lawyers-tax-advisors-auditors-en","category-lawyers-tax-consultants-auditors","category-investors"],"yoast_head":"\n